IRadimed Corporation
IRadimed Corporation (IRMD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
irmd · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for IRadimed Corporation (IRMD) measures how much investors pay for each dollar of the company's trailing earnings. IRMD's current PE ratio of 51.10x is calculated by dividing its stock price of $94.39 by its TTM earnings per share of $1.85. +18.9% elevated vs 5Y avg 43.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 14 fiscal years · Front-end computedMinQ1 · 25%50.1x
MedianQ3 · 75%322.5x
Max
At 51.10x, IRMD's current P/E is within its average historical range over the past 14 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
IRadimed CorporationYou IRMD | $1.2B | 51.10x | — | $1.85 |
 AdaptHealth Corp. AHCO | $1.3B | N/A | — | -$0.52 |
 AxoGen, Inc. AXGN | $2.2B | N/A | — | -$0.34 |
 Cronos Group Inc. CRON | $1.0B | N/A | — | -$0.02 |
 Claritev Corporation CTEV | $461M | N/A | — | -$17.30 |
 GoodRx Holdings, Inc. GDRX | $912M | 31.72x | — | $0.09 |
 Integra LifeSciences Holdings Corporation IART | $1.3B | N/A | — | -$6.73 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 55.05x | $1.77 | +52.0% | |
2024-12-31 FY2024 | 36.23x | $1.52 | +4.1% | |
2023-12-31 FY2023 | 34.80x | $1.36 | +25.6% | |
2022-12-31 FY2022 | 27.70x | $1.02 | -54.7% | |
2021-12-31 FY2021 | 61.18x | $0.76 | -69.7% | |
2020-12-31 FY2020 | 201.91x | $0.11 | +637.2% | |
2019-12-31 FY2019 | 27.39x | $0.85 | -41.7% | |
2018-12-31 FY2018 | 46.99x | $0.52 | -85.4% | |
2017-12-31 FY2017 | 322.51x | $0.05 | +1837.6% | |
2016-12-31 FY2016 | 16.64x | $0.67 | -59.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for IRadimed Corporation (IRMD) measures how much investors pay for each dollar of the company's trailing earnings. IRMD's current PE ratio of 51.10x is calculated by dividing its stock price of $94.39 by its TTM earnings per share of $1.85.
Frequently asked questions
IRMD pe ratio · 6 questionsIRMD's current PE ratio is 51.10x as of 2026-06-09, based on a stock price of $94.39 and TTM EPS of $1.85. Data sourced from Financial Modeling Prep via IRMD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · IRadimed Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09